IGF1R
Insulin-like growth factor 1 receptor
Also known as: CD221, IGF1R_HUMAN, IGFIR, IGFR, JTK13, MGC18216
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P08069
- Gene
- IGF1R
- Ensembl
- ENSG00000140443
- Chromosome
- 15
- Canonical length
- 1367 aa
- Protein class
- Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins
- Subcellular location
- Nucleoli,Nucleoli rim,Plasma membrane,Primary cilium
OverviewNCBI Gene
This receptor binds insulin-like growth factor with a high affinity. It has tyrosine kinase activity. The insulin-like growth factor I receptor plays a critical role in transformation events. Cleavage of the precursor generates alpha and beta subunits. It is highly overexpressed in most malignant tissues where it functions as an anti-apoptotic agent by enhancing cell survival. Alternatively spliced transcript variants encoding distinct isoforms have been found for this gene. [provided by RefSeq, May 2014]
Canonical amino-acid sequenceUniProt
1367 residues, UniProt reviewed canonical sequence.
>P08069|IGF1R
1 MKSGSGGGSP TSLWGLLFLS AALSLWPTSG EICGPGIDIR NDYQQLKRLE NCTVIEGYLH
61 ILLISKAEDY RSYRFPKLTV ITEYLLLFRV AGLESLGDLF PNLTVIRGWK LFYNYALVIF
121 EMTNLKDIGL YNLRNITRGA IRIEKNADLC YLSTVDWSLI LDAVSNNYIV GNKPPKECGD
181 LCPGTMEEKP MCEKTTINNE YNYRCWTTNR CQKMCPSTCG KRACTENNEC CHPECLGSCS
241 APDNDTACVA CRHYYYAGVC VPACPPNTYR FEGWRCVDRD FCANILSAES SDSEGFVIHD
301 GECMQECPSG FIRNGSQSMY CIPCEGPCPK VCEEEKKTKT IDSVTSAQML QGCTIFKGNL
361 LINIRRGNNI ASELENFMGL IEVVTGYVKI RHSHALVSLS FLKNLRLILG EEQLEGNYSF
421 YVLDNQNLQQ LWDWDHRNLT IKAGKMYFAF NPKLCVSEIY RMEEVTGTKG RQSKGDINTR
481 NNGERASCES DVLHFTSTTT SKNRIIITWH RYRPPDYRDL ISFTVYYKEA PFKNVTEYDG
541 QDACGSNSWN MVDVDLPPNK DVEPGILLHG LKPWTQYAVY VKAVTLTMVE NDHIRGAKSE
601 ILYIRTNASV PSIPLDVLSA SNSSSQLIVK WNPPSLPNGN LSYYIVRWQR QPQDGYLYRH
661 NYCSKDKIPI RKYADGTIDI EEVTENPKTE VCGGEKGPCC ACPKTEAEKQ AEKEEAEYRK
721 VFENFLHNSI FVPRPERKRR DVMQVANTTM SSRSRNTTAA DTYNITDPEE LETEYPFFES
781 RVDNKERTVI SNLRPFTLYR IDIHSCNHEA EKLGCSASNF VFARTMPAEG ADDIPGPVTW
841 EPRPENSIFL KWPEPENPNG LILMYEIKYG SQVEDQRECV SRQEYRKYGG AKLNRLNPGN
901 YTARIQATSL SGNGSWTDPV FFYVQAKTGY ENFIHLIIAL PVAVLLIVGG LVIMLYVFHR
961 KRNNSRLGNG VLYASVNPEY FSAADVYVPD EWEVAREKIT MSRELGQGSF GMVYEGVAKG
1021 VVKDEPETRV AIKTVNEAAS MRERIEFLNE ASVMKEFNCH HVVRLLGVVS QGQPTLVIME
1081 LMTRGDLKSY LRSLRPEMEN NPVLAPPSLS KMIQMAGEIA DGMAYLNANK FVHRDLAARN
1141 CMVAEDFTVK IGDFGMTRDI YETDYYRKGG KGLLPVRWMS PESLKDGVFT TYSDVWSFGV
1201 VLWEIATLAE QPYQGLSNEQ VLRFVMEGGL LDKPDNCPDM LFELMRMCWQ YNPKMRPSFL
1261 EIISSIKEEM EPGFREVSFY YSEENKLPEP EELDLEPENM ESVPLDPSAS SSSLPLPDRH
1321 SGHKAENGPG PGVLVLRASF DERQPYAHMN GGRKNERALP LPQSSTCLocalizationUniProt · AlphaFold · HPA
Whether an antibody against IGF1R can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.34
- Highest tissue expression
- 19 nTPM
Expression across tissuesHPA
Tissue
- blood vessel: 19 nTPM
- retina: 15 nTPM
- ovary: 15 nTPM
- pancreas: 15 nTPM
- prostate: 14 nTPM
- fallopian tube: 12 nTPM
Single-cell type
- neutrophils: 2,488 nCPM
- proximal tubule cells: 1,339 nCPM
- podocytes: 1,295 nCPM
- prostatic glandular cells: 1,130 nCPM
- neutrophil progenitors: 976 nCPM
- choroid plexus epithelial cells: 876 nCPM
Immune cell
- neutrophil: 4.3 nTPM
- basophil: 1.8 nTPM
- naive CD4 T-cell: 1.4 nTPM
- eosinophil: 0.9 nTPM
- NK-cell: 0.5 nTPM
- gdT-cell: 0.4 nTPM
Brain region
- choroid plexus: 94 nTPM
- midbrain: 47 nTPM
- thalamus: 46 nTPM
- cerebellum: 44 nTPM
- medulla oblongata: 43 nTPM
- cerebral cortex: 43 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about IGF1R.
Disease | AllUniProt
Conditions IGF1R is implicated in, by any mechanism.
- Insulin-like growth factor 1 resistance (IGF1RES) MIM:270450
Disease | GeneticClinVar
78 pathogenic / likely-pathogenic of 1,344 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Growth delay due to insulin-like growth factor I resistance
- Inborn genetic diseases
- Neurodevelopmental disorder
- IGF1R-related disorder
- Intellectual disability
Disease | AutoantibodyPubMed
Conditions in which antibodies against IGF1R are reported. Each links to that disease's full target list.
Showing 1 of 2 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for IGF1R from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
16 publications
- TSH/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy Pathogenesis.
2016 · J Clin Endocrinol Metab · RCR 5.3 · 117 citations - Mechanisms in Thyroid Eye Disease: The TSH Receptor Interacts Directly With the IGF-1 Receptor.
2025 · Endocrinology · RCR 2.9 · 8 citations - Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.
2019 · J Endocrinol Invest · RCR 2.9 · 49 citations - Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy.
2021 · Front Endocrinol (Lausanne) · RCR 2.9 · 37 citations - Autoantibodies to the IGF1 receptor in Graves' orbitopathy.
2013 · J Clin Endocrinol Metab · RCR 2.6 · 70 citations
Show 11 more
- A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in graves' orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody.
2012 · J Clin Endocrinol Metab · RCR 2.4 · 65 citations - Orbital fibrosis in a mouse model of Graves' disease induced by genetic immunization of thyrotropin receptor cDNA.
2011 · J Endocrinol · RCR 2.3 · 69 citations - Precision Medicine in Graves' Disease and Ophthalmopathy.
2021 · Front Pharmacol · RCR 2.1 · 25 citations - Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.
2022 · Thyroid · RCR 1.8 · 20 citations - Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves' Disease: results of a pilot study.
2020 · J Endocrinol Invest · RCR 1.5 · 22 citations - Antibodies to insulin-like growth factor I receptors in diabetes and other disorders.
1988 · Diabetes · RCR 0.8 · 25 citations - Teprotumumab for the treatment of thyroid eye disease.
2023 · Expert Opin Biol Ther · RCR 0.5 · 3 citations - Thyroid dermopathy and thyroid eye disease associated with hypofunctional autoimmune thyroid disease with high TSI/anti-TSHR antibodies improved with teprotumumab.
2024 · BMJ Case Rep · RCR 0.5 · 2 citations - Endocrine autoimmune diseases.
1994 · Neth J Med · RCR 0.1 · 3 citations - Low prevalence of autoantibodies to the insulin-like growth factor I receptor in children with short stature.
1992 · Pediatr Res · RCR 0 · 2 citations - In vivo and in vitro evidence for a protective role of autoantibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' orbitopathy.
2025 · Endocrine
Reference: B cellIEDB
1 publication
- Peptide microarray-based characterization of antibody responses to host proteins after bacille Calmette-Guérin vaccination.
2017 · Int J Infect Dis · RCR 0.7 · 19 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.31
- gnomAD pLI
- 0.97
- gnomAD missense Z
- 2.73
- DepMap mean gene effect
- -0.31
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- amyloid-beta clearance
- cellular response to amyloid-beta
- cellular response to glucose stimulus
- dendritic spine maintenance
- immune response
- insulin receptor signaling pathway
- insulin-like growth factor receptor signaling pathway
- negative regulation of apoptotic process
- negative regulation of MAPK cascade
- peptidyl-tyrosine autophosphorylation
- phosphatidylinositol 3-kinase/protein kinase B signal transduction
- positive regulation of cell migration
- positive regulation of cell population proliferation
- positive regulation of cold-induced thermogenesis
- positive regulation of MAPK cascade
- positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction
- positive regulation of protein-containing complex disassembly
- protein autophosphorylation
- regulation of JNK cascade
- signal transduction
- transcytosis
Molecular functions
- ATP binding
- identical protein binding
- insulin binding
- insulin receptor activity
- insulin receptor binding
- insulin receptor substrate binding
- insulin-like growth factor binding
- insulin-like growth factor I binding
- insulin-like growth factor receptor activity
- phosphatidylinositol 3-kinase binding
- protein transporter activity
- protein tyrosine kinase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Receptor L-domain
- Protein kinase domain
- Serine-threonine/tyrosine-protein kinase, catalytic domain
- Tyrosine-protein kinase, receptor class II, conserved site
- Fibronectin type III
- Furin-like cysteine-rich domain
- Furin-like repeat
- Tyrosine-protein kinase, active site
- Growth factor receptor cysteine-rich domain superfamily
- Protein kinase-like domain superfamily
- Immunoglobulin-like fold
- Tyrosine-protein kinase, insulin-like receptor
- Protein kinase, ATP binding site
- Tyrosine-protein kinase, catalytic domain
- Fibronectin type III superfamily
- Receptor L-domain superfamily
- Receptor Tyrosine Kinase
- Furin-like cysteine rich region
- Receptor L domain
- Protein tyrosine and serine/threonine kinase
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of IGF1R in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads IGF1R as an antibody target. Whether an autoantibody or antibody against IGF1R could matter depends on whether native IGF1R is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
IGF1R is annotated at the cell surface, where native IGF1R is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label IGF1R as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...